Tonix Pharmaceuticals (TNXP)
(Delayed Data from NSDQ)
$0.15 USD
0.00 (-1.60%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.14 -0.01 (-5.08%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TNXP 0.15 0.00(-1.60%)
Will TNXP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TNXP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TNXP
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
TNXP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TNXP
Tonix Pharmaceuticals files $300M mixed securities shelf
Tonix Pharmaceuticals announces issuance of U.S. patent on Tosymra
New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution
Tonix Pharma Advances Promising Mpox Vaccine Candidate
Tonix announces single dose of TNX-801 aligns with WHO Preferred TPP